<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: certain risk factors", fill: "#add8e6"},
{source: "1: certain risk factors", target: "1: could affect", fill: "#add8e6"},
{source: "1: could affect", target: "1: operations", fill: "#add8e6"},
{source: "1: certain risk factors", target: "6: December ", fill: "#cb6d51"},
{source: "6: December ", target: "9: profitability will depend on", fill: "#ff6700"},
{source: "9: profitability will depend on", target: "9: control costs", fill: "#ff6700"},
{source: "9: control costs", target: "9: effectively integrate", fill: "#ff6700"},
{source: "9: effectively integrate", target: "9: businesses", fill: "#ff6700"},
{source: "9: businesses", target: "9: adequate insurance against malpractice", fill: "#ff6700"},
{source: "9: adequate insurance against malpractice", target: "9: economic conditions", fill: "#ff6700"},
{source: "9: economic conditions", target: "9: availability", fill: "#ff6700"},
{source: "9: availability", target: "9: discretionary income", fill: "#ff6700"},
{source: "9: discretionary income", target: "9: concerns about", fill: "#ff6700"},
{source: "9: concerns about", target: "9: effectiveness", fill: "#ff6700"},
{source: "9: effectiveness", target: "9: laser vision", fill: "#ff6700"},
{source: "9: laser vision", target: "9: correction", fill: "#ff6700"},
{source: "9: correction", target: "9: competitive factors", fill: "#ff6700"},
{source: "9: competitive factors", target: "9: regulatory developments", fill: "#ff6700"},
{source: "9: regulatory developments", target: "9: attract qualified personnel", fill: "#ff6700"},
{source: "9: attract qualified personnel", target: "9: doctors apos", fill: "#ff6700"},
{source: "9: doctors apos", target: "9: at reasonable rates", fill: "#ff6700"},
{source: "9: profitability will depend on", target: "12: laser vision correction procedures", fill: "#f5fffa"},
{source: "12: laser vision correction procedures", target: "12: by health care insurance companies", fill: "#f5fffa"},
{source: "12: by health care insurance companies", target: "12: thirdparty payors", fill: "#f5fffa"},
{source: "12: laser vision correction procedures", target: "17: compete with hospitals", fill: "#5d8aa8"},
{source: "17: compete with hospitals", target: "17: ophthalmologists", fill: "#5d8aa8"},
{source: "17: ophthalmologists", target: "17: corporate laser", fill: "#5d8aa8"},
{source: "17: corporate laser", target: "17: manufacturers", fill: "#5d8aa8"},
{source: "17: manufacturers", target: "17: excimer laser equipment", fill: "#5d8aa8"},
{source: "17: excimer laser equipment", target: "17: offering laser vision", fill: "#5d8aa8"},
{source: "17: offering laser vision", target: "17: correction services", fill: "#5d8aa8"},
{source: "17: correction services", target: "17: excimer lasers", fill: "#5d8aa8"},
{source: "17: compete with hospitals", target: "21: addition competition", fill: "#f3c"},
{source: "21: addition competition", target: "21: would increase", fill: "#f3c"},
{source: "21: would increase", target: "21: provincial laws", fill: "#f3c"},
{source: "21: provincial laws", target: "21: permit optometrists", fill: "#f3c"},
{source: "21: permit optometrists", target: "21: ophthalmologists", fill: "#f3c"},
{source: "21: ophthalmologists", target: "21: laser vision correction", fill: "#f3c"},
{source: "21: addition competition", target: "START_HERE", fill: "#f3c"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December">December</a></td>
      <td>December is the twelfth and the final month of the year in the Julian and Gregorian calendars. It is also the last of seven months to have a length of 31 days.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_17">December 17</a></td>
      <td>December 17 is the 351st day of the year (352nd in leap years) in the Gregorian calendar;  14 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n497 BC – The first Saturnalia festival was celebrated in ancient Rome.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_10">December 10</a></td>
      <td>December 10 is the 344th day of the year (345th in leap years) in the Gregorian calendar;  21 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n1317 – The "Nyköping Banquet": King Birger of Sweden treacherously seizes his two brothers Valdemar, Duke of Finland and Eric, Duke of Södermanland, who were subsequently starved to death in the dungeon of Nyköping Castle.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_1">December 1</a></td>
      <td>December is the twelfth and the final month of the year in the Julian and Gregorian calendars. It is also the last of seven months to have a length of 31 days.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2016_in_aviation">2016 in aviation</a></td>
      <td>This is a list of aviation-related events from 2016.\n\n\n== Events ==\n\n\n=== January ===\nThe Government of Italy permitted United States unmanned aerial vehicles (UAVs or drones) to fly strike missions from Naval Air Station Sigonella in Sicily where the US has operated unarmed surveillance UAVs since 2001 against Islamic State targets in Libya, but only if they are "defensive," protecting U.S. forces or rescuers retrieving downed pilots.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_1924_German_federal_election">December 1924 German federal election</a></td>
      <td>Federal elections were held in Germany on 7 December 1924, the second that year after the Reichstag had been dissolved on 20 October. The Social Democratic Party remained the largest party in the Reichstag, receiving an increased share of the vote and winning 131 of the 493 seats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_7">December 7</a></td>
      <td>December 3 is the 337th day of the year (338th in leap years) in the Gregorian calendar;  28 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n915 – Pope John X crowns Berengar I of Italy as Holy Roman Emperor (probable date).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_18">December 18</a></td>
      <td>December 11 is the 345th day of the year (346th in leap years) in the Gregorian calendar;  20 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n220 – Emperor Xian of Han is forced to abdicate the throne by Cao Cao's son Cao Pi, ending the Han dynasty.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_26">December 26</a></td>
      <td>December 15 is the 349th day of the year (350th in leap years) in the Gregorian calendar;  16 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n533 – Vandalic War: Byzantine general Belisarius defeats the Vandals, commanded by King Gelimer, at the Battle of Tricamarum.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_12">December 12</a></td>
      <td>December 12 is the 346th day of the year (347th in leap years) in the Gregorian calendar;  19 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n627 – Battle of Nineveh: A Byzantine army under Emperor Heraclius defeats Emperor Khosrau II's Persian forces, commanded by General Rhahzadh.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/LASIK">LASIK</a></td>
      <td>LASIK or Lasik (laser-assisted in situ keratomileusis), commonly referred to as laser eye surgery or laser vision correction, is a type of refractive surgery for the correction of myopia, hyperopia, and an actual cure for astigmatism, since it is in the cornea. LASIK surgery is performed by an ophthalmologist who uses a laser or microkeratome to reshape the eye's cornea in order to improve visual acuity.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Laser_blended_vision">Laser blended vision</a></td>
      <td>Laser blended vision is a sophisticated laser eye treatment which is used to treat presbyopia (ageing eyes; progressive loss of the ability to focus on nearby objects) or other age-related eye conditions.  It can be used to help people that simply need reading glasses, and also those who have started to need bifocal or varifocal spectacle correction due to ageing changes in the eye.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Johnson_&amp;_Johnson_Vision">Johnson &amp; Johnson Vision</a></td>
      <td>Johnson &amp; Johnson Vision (JJV) is a subsidiary of Johnson &amp; Johnson and is composed of two divisions, Johnson &amp; Johnson Surgical Vision and Johnson &amp; Johnson Vision Care (Contact Lens).  Services include Intraocular lenses, laser vision correction systems, phacoemulsification systems, viscoelastic, Microkeratomes and related products used in cataract and refractive surgery.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Laser_pointer">Laser pointer</a></td>
      <td>Laser printing is an electrostatic digital printing process. It produces high-quality text and graphics (and moderate-quality photographs) by repeatedly passing a laser beam back and forth over a negatively-charged cylinder called a "drum" to define a differentially-charged image.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gamma_correction">Gamma correction</a></td>
      <td>Gamma correction or gamma is a nonlinear operation used to encode and decode luminance or tristimulus values in video or still image systems. Gamma correction is, in the simplest cases, defined by the following power-law expression:\n\n  \n    \n      \n        \n          V\n          \n            out\n          \n        \n        =\n        A\n        \n          V\n          \n            in\n          \n          \n            γ\n          \n        \n        ,\n      \n    \n    {\displaystyle V_{\text{out}}=AV_{\text{in}}^{\gamma },}\n  where the non-negative real input value \n  \n    \n      \n        \n          V\n          \n            in\n          \n        \n      \n    \n    {\displaystyle V_{\text{in}}}\n   is raised to the power \n  \n    \n      \n        γ\n      \n    \n    {\displaystyle \gamma }\n   and multiplied by the constant A to get the output value \n  \n    \n      \n        \n          V\n          \n            out\n          \n        \n      \n    \n    {\displaystyle V_{\text{out}}}\n  .</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bonferroni_correction">Bonferroni correction</a></td>
      <td>In statistics, the Bonferroni correction is a method to counteract the multiple comparisons problem. Bonferroni correction is the simplest method for counteracting this; however, it is a conservative method that gives greater risk of failure to reject a false null hypothesis than other methods, as it ignores potentially valuable information, such as the distribution of p-values across all comparisons (which, if the null hypothesis is correct for all comparisons, is expected to take uniform distribution).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Corrections">Corrections</a></td>
      <td>In criminal justice, particularly in North America, correction, corrections, and correctional, are umbrella terms describing a variety of functions typically carried out by government agencies, and involving the punishment, treatment, and supervision of persons who have been convicted of crimes. These functions commonly include imprisonment, parole, and probation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bessel's_correction">Bessel's correction</a></td>
      <td>In statistics, Bessel's correction is the use of n − 1 instead of n in the formula for the sample variance and sample standard deviation, where n is the number of observations in a sample. This method corrects the bias in the estimation of the population variance.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Greenhouse–Geisser_correction">Greenhouse–Geisser correction</a></td>
      <td>The Greenhouse–Geisser correction \n  \n    \n      \n        \n          \n            \n              ε\n              ^\n            \n          \n        \n      \n    \n    {\displaystyle {\widehat {\varepsilon }}}\n   is a statistical method of adjusting for lack of sphericity in a repeated measures ANOVA. The correction functions as both an estimate of epsilon (sphericity) and a correction for lack of sphericity. The correction was proposed by Samuel Greenhouse and Seymour Geisser in 1959.The Greenhouse–Geisser correction is an estimate of sphericity (\n  \n    \n      \n        \n          \n            \n              ε\n              ^\n            \n          \n        \n      \n    \n    {\displaystyle {\widehat {\varepsilon }}}\n  ).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/End_correction">End correction</a></td>
      <td>Whenever a wave forms through a medium/object (organ pipe) with a closed/open end, there is a chance of error in the formation of the wave, i.e. it may not actually start from the opening of the object but instead before the opening, thus resulting on an error when studying it theoretically.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prism_correction">Prism correction</a></td>
      <td>Eye care professionals use prism correction as a component of some eyeglass prescriptions.  A lens which includes some amount of prism correction will displace the viewed image horizontally, vertically, or a combination of both directions.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pitch_correction">Pitch correction</a></td>
      <td>Pitch correction is an electronic effects unit or audio software that changes the intonation (highness or lowness in pitch) of an audio signal so that all pitches will be notes from the equally tempered system (i.e., like the pitches on a piano). Pitch correction devices do this without affecting other aspects of its sound.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/LCA-Vision">LCA-Vision</a></td>
      <td>LCA-Vision is a provider of photorefractive keratectomy in the United States under the LasikPlus brand.  The company performs Custom LASIK, PRK and monovision treatment to correct nearsightedness, farsightedness, astigmatism and reduce the effects of presbyopia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/LASIK_MD">LASIK MD</a></td>
      <td>LASIK MD is a North America provider of laser vision correction and the largest provider of laser vision correction in North America based on procedure volume. As of 2013, LASIK MD performs over sixty percent of all laser vision correction procedures in Canada.LASIK MD was founded in 2001 by Dr.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Mark_Cohen_(surgeon)">Mark Cohen (surgeon)</a></td>
      <td>Mark Cohen is a Canadian laser eye surgeon who practices in Montreal and Toronto. In 2001, he and Avi Wallerstein founded LASIK MD, Canada's largest provider of laser refractive surgery.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Refractive_surgery">Refractive surgery</a></td>
      <td>Refractive eye surgery is optional eye surgery used to improve the refractive state of the eye and decrease or eliminate dependency on glasses or contact lenses. This can include various methods of surgical remodeling of the cornea (keratomileusis), lens implantation or lens replacement.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Eye_care_professional">Eye care professional</a></td>
      <td>An eye care professional (ECP) is an individual who provides a service related to the eyes or vision. It is any healthcare worker involved in eye care, from one with a small amount of post-secondary training to practitioners with a doctoral level of education.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emil_Chynn">Emil Chynn</a></td>
      <td>Emil William Chynn (born October 7, 1965) is a Chinese-American LASEK surgeon, author, researcher, and media personality. He has also appeared in Millionaire Matchmaker.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Schirmer's_test">Schirmer's test</a></td>
      <td>Schirmer's test determines whether the eye produces enough tears to keep it moist. This test is used when a person experiences very dry eyes or excessive watering of the eyes.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>TLC VISION CORP    ITEM 1A RISK FACTORS         The following are <font color="blue">certain risk factors</font> that <font color="blue">could affect</font> our business,  financial results and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">risk factors should</font> be  considered in <font color="blue"><font color="blue"><font color="blue">connection</font> with</font> evaluating</font> the forward-looking statements  contained in this <font color="blue">Annual Report </font>on Form 10-K because these <font color="blue">factors could</font> cause  the actual results and <font color="blue">conditions</font> to <font color="blue">differ materially from</font> those projected in  forward-looking statements</td>
    </tr>
    <tr>
      <td>The risks that we have <font color="blue">highlighted</font> here are not the  only ones that we face</td>
    </tr>
    <tr>
      <td>If any of the <font color="blue">risks actually</font> occur, our business,  <font color="blue">financial condition</font> or results of <font color="blue">operations</font> could be <font color="blue">negatively affected</font></td>
    </tr>
    <tr>
      <td>In  that case, the <font color="blue">trading price</font> of our <font color="blue">stock could decline</font>, and our <font color="blue">stockholders</font>  may lose all or part of their <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>WE HAVE REPORTED ACCUMULATED DEFICITS; OUR FUTURE PROFITABILITY IS  UNCERTAIN         We reported a net loss of dlra9dtta4 million for the year ended <font color="blue">December </font>31,  2003</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we reported an <font color="blue">accumulated deficit</font> of dlra244dtta2  million</td>
    </tr>
    <tr>
      <td>Even though we reported net income of dlra6dtta9 million and dlra43dtta7 million  for the years ended <font color="blue">December </font>31, 2005 and 2004, respectively, we may not be able  to <font color="blue">sustain <font color="blue">profitability</font></font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">profitability</font> will depend on</font> a number of factors,  including:         -    demand for our services;         -    our ability to <font color="blue">control costs</font>;         -    our ability to execute our strategy and <font color="blue"><font color="blue">effective</font>ly integrate</font> acquired            <font color="blue">businesses</font> and assets;         -    our ability to obtain <font color="blue"><font color="blue">adequate insurance</font> against malpractice</font> claims            and reduce the number of claims;         -    economic <font color="blue">conditions</font> in the markets in which we compete, including the            <font color="blue">availability</font> of <font color="blue">discretionary income</font>;         -    <font color="blue">concerns about</font> the safety and <font color="blue"><font color="blue">effective</font>ness</font> of <font color="blue">laser vision</font>            <font color="blue">correction</font>;         -    <font color="blue"><font color="blue">competitive</font> factors</font>;         -    <font color="blue"><font color="blue">regulatory</font> <font color="blue">developments</font></font>;         -    our ability to retain and <font color="blue">attract qualified personnel</font>; and         -    doctors &amp;apos  ability to obtain <font color="blue"><font color="blue">adequate insurance</font> against malpractice</font>            claims <font color="blue">at reasonable rates</font></td>
    </tr>
    <tr>
      <td>In addition, our subsidiary OccuLogix expects to report <font color="blue"><font color="blue">significant</font> net</font>  losses for the <font color="blue">next <font color="blue">several years</font></font></td>
    </tr>
    <tr>
      <td>We will be required to report the financial  results of OccuLogix on a <font color="blue"><font color="blue">consolidated</font> basis as long as</font> we have a <font color="blue">controlling</font>  <font color="blue">financial interest</font></td>
    </tr>
    <tr>
      <td>CHANGES IN GENERAL ECONOMIC CONDITIONS MAY CAUSE FLUCTUATIONS IN OUR       REVENUES AND PROFITABILITY         The cost of <font color="blue">laser vision</font> <font color="blue">correction</font> procedures is typically not reimbursed  <font color="blue">by <font color="blue">health care</font> insurance companies</font> or other third-party payors</td>
    </tr>
    <tr>
      <td>Accordingly, our  operating results <font color="blue">may vary based upon</font> the impact of changes in economic  <font color="blue">conditions</font> on the <font color="blue">disposable income</font> of <font color="blue">consumers interested</font> in <font color="blue">laser vision</font>  <font color="blue">correction</font></td>
    </tr>
    <tr>
      <td>A <font color="blue"><font color="blue">significant</font> decrease</font> in consumer <font color="blue">disposable income</font> in a weakening  <font color="blue">economy may</font> result in <font color="blue">decreased procedure levels</font> and revenues</td>
    </tr>
    <tr>
      <td>In addition,  weakening economic <font color="blue">conditions</font> may result in an increase in the number of our  customers, who experience <font color="blue">financial distress</font> or declare bankruptcy, which may  <font color="blue">negatively impact</font> our <font color="blue">accounts receivable collection</font> experience</td>
    </tr>
    <tr>
      <td>THE MARKET FOR LASER VISION CORRECTION IS INTENSELY COMPETITIVE AND       COMPETITION MAY INCREASE         Some of our <font color="blue">competitors</font> or companies that may choose to enter the industry  in the future, including laser <font color="blue">manufacturers</font> themselves, may have <font color="blue">substantially</font>  greater financial, technical, managerial, marketing and/or other resources and  experience than us and may compete more <font color="blue"><font color="blue">effective</font>ly than</font> we are able to compete</td>
    </tr>
    <tr>
      <td>We <font color="blue">compete with hospitals</font>, individual <font color="blue">ophthalmologists</font>, other <font color="blue">corporate laser</font>  centers and <font color="blue">manufacturers</font> of <font color="blue"><font color="blue">excimer laser</font> equipment</font> in offering <font color="blue">laser vision</font>  <font color="blue">correction</font> services and access to <font color="blue"><font color="blue">excimer laser</font>s</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">principal corporate</font>  <font color="blue">competitors</font> include LCA-Vision Inc</td>
    </tr>
    <tr>
      <td>and Lasik Vision Institute, Inc</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>in the market for <font color="blue">laser vision</font> <font color="blue">correction</font> could increase as  <font color="blue"><font color="blue">excimer laser</font> surgery becomes</font> more commonplace and the number of  <font color="blue">ophthalmologists</font> performing the <font color="blue">procedure increases</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">competition</font>  <font color="blue">would increase</font> if state or <font color="blue">provincial laws</font> were amended to <font color="blue">permit <font color="blue">optometrists</font></font>,  in addition to <font color="blue">ophthalmologists</font>, to perform <font color="blue">laser vision</font> <font color="blue">correction</font></td>
    </tr>
    <tr>
      <td>We will  <font color="blue">compete on</font> the basis of quality of service, surgeon skill and reputation and  price</td>
    </tr>
    <tr>
      <td>If more providers offer <font color="blue">laser vision</font> <font color="blue">correction</font> in a <font color="blue">given geographic</font>  market, the <font color="blue">price charged</font> for <font color="blue">such procedures may decrease</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>have  offered <font color="blue">laser vision</font> <font color="blue">correction</font> at prices considerably                                             19    <PAGE>    lower than our prices</td>
    </tr>
    <tr>
      <td>The <font color="blue">laser vision</font> <font color="blue">correction</font> industry has been  <font color="blue"><font color="blue">significant</font>ly affected by <font color="blue">reductions</font></font> in the price for <font color="blue">laser vision</font> <font color="blue">correction</font>,  including the failure of many <font color="blue">businesses</font> that provided <font color="blue">laser vision</font> <font color="blue">correction</font></td>
    </tr>
    <tr>
      <td>Market <font color="blue">conditions</font> may compel us to <font color="blue">lower prices</font> in our centers to remain  <font color="blue">competitive</font> and any reduction in our <font color="blue">prices may</font> not be <font color="blue">offset by</font> an increase in  our <font color="blue">procedure volume</font> or <font color="blue">decreases</font> in our costs</td>
    </tr>
    <tr>
      <td>A decrease in either the fees or  procedures performed at our <font color="blue">eye care centers</font> or in the number of procedures  performed at our <font color="blue">centers could</font> cause our revenues to decline and our business  and <font color="blue">financial condition</font> to weaken</td>
    </tr>
    <tr>
      <td>Laser vision <font color="blue">correction</font> competes with other surgical and non-surgical means  of <font color="blue">correcting refractive disorders</font>, including <font color="blue">eyeglasses</font>, contact lenses, other  types of <font color="blue">refractive surgery</font> and other <font color="blue"><font color="blue">technologies</font> currently available</font> and under  development, such as intraocular lenses and <font color="blue">surgery with different types</font> of  lasers</td>
    </tr>
    <tr>
      <td>Our <font color="blue">management</font>, <font color="blue">operations</font> and marketing plans may not be successful in  meeting this <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td>Certain <font color="blue">competitive</font> optometry chains and other  suppliers of <font color="blue">eyeglasses</font> and <font color="blue">contact lenses may</font> have <font color="blue">substantially</font> greater  financial, technical, managerial, marketing and other resources and experience  than we have and <font color="blue">may promote <font color="blue">alternative</font>s</font> to <font color="blue">laser vision</font> <font color="blue">correction</font> or purchase  <font color="blue">laser systems</font> and offer <font color="blue">laser vision</font> <font color="blue">correction</font> to their customers</td>
    </tr>
    <tr>
      <td>If the price of excimer <font color="blue">laser systems</font> <font color="blue">decreases</font>, <font color="blue">additional</font> <font color="blue">competition</font>  could develop</td>
    </tr>
    <tr>
      <td>The price for excimer <font color="blue">laser systems</font> could decrease for a number  of reasons, including <font color="blue">technological innovation</font> and increased <font color="blue">competition</font> among  laser <font color="blue">manufacturers</font></td>
    </tr>
    <tr>
      <td>Further <font color="blue">reductions</font> in the price of <font color="blue"><font color="blue">excimer laser</font>s</font> could  <font color="blue">reduce demand</font> for our <font color="blue">laser access services by</font> making it <font color="blue">economically</font> more  attractive for <font color="blue">eye surgeons</font> to buy <font color="blue"><font color="blue">excimer laser</font>s</font> rather than utilize our  services</td>
    </tr>
    <tr>
      <td>Most <font color="blue"><font color="blue">affiliated</font> surgeons</font> performing <font color="blue">laser vision</font> <font color="blue">correction</font> at our centers  and our <font color="blue"><font color="blue">significant</font> employees</font> have agreed to <font color="blue">restrictions on competing with us</font>,  or <font color="blue">soliciting patients</font> or <font color="blue">employees associated with</font> their <font color="blue">facilities</font>; however,  these non-<font color="blue">competition</font> <font color="blue">agreements</font> may not be enforceable</td>
    </tr>
    <tr>
      <td>THE MARKET ACCEPTANCE OF LASER VISION CORRECTION IS UNCERTAIN         We believe that the <font color="blue">profitability</font> and growth of our <font color="blue">company will depend</font>  <font color="blue">upon broad acceptance</font> of <font color="blue">laser vision</font> <font color="blue">correction</font> in the <font color="blue"><font color="blue">United States</font> </font>and, to a  <font color="blue">lesser extent</font>, Canada</td>
    </tr>
    <tr>
      <td>We may have <font color="blue">difficulty generating revenue</font> and growing our  business if <font color="blue">laser vision</font> <font color="blue">correction</font> does not become more <font color="blue"><font color="blue">widely accepted</font> by</font> the  <font color="blue">general population as</font> an <font color="blue">alternative</font> to <font color="blue">existing methods</font> of <font color="blue">treating refractive</font>  <font color="blue">vision disorders</font></td>
    </tr>
    <tr>
      <td>Laser vision <font color="blue">correction</font> may not become more <font color="blue">widely accepted</font>  due to a number of factors, including:         -    its cost, particularly since <font color="blue">laser vision</font> <font color="blue">correction</font> typically is not            <font color="blue"><font color="blue">covered by</font> <font color="blue">government</font></font> or <font color="blue">private insurers</font>;         -    <font color="blue">general resistance</font> to surgery;         -    the fact that <font color="blue">effective</font> and less expensive <font color="blue">alternative</font> methods of            correcting refractive <font color="blue">vision disorders</font> are <font color="blue">widely available</font>;         -    the lack of long-term follow-up data;         -    the <font color="blue">possibility</font> of unknown side effects; and         -    reported <font color="blue">adverse events</font> or other <font color="blue">unfavorable publicity involving</font>            patient outcomes from <font color="blue">laser vision</font> <font color="blue">correction</font></td>
    </tr>
    <tr>
      <td>CONCERNS ABOUT POTENTIAL SIDE EFFECTS AND LONG-TERM RESULTS OF LASER VISION       CORRECTION MAY NEGATIVELY IMPACT MARKET ACCEPTANCE OF LASER VISION       CORRECTION AND PREVENT US FROM GROWING OUR BUSINESS         Concerns have <font color="blue">been raised with respect</font> to the <font color="blue">predictability</font> and stability  of results and <font color="blue">potential <font color="blue">complications</font></font> or side effects of <font color="blue">laser vision</font>  <font color="blue">correction</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">complications</font> or side effects of <font color="blue">laser vision</font> <font color="blue">correction</font> may  <font color="blue">call into question</font> the safety and <font color="blue"><font color="blue">effective</font>ness</font> of <font color="blue">laser vision</font> <font color="blue">correction</font>,  which in turn may damage the likelihood of <font color="blue">market acceptance</font> of <font color="blue">laser vision</font>  <font color="blue">correction</font></td>
    </tr>
    <tr>
      <td><font color="blue">Complications </font>or side effects of <font color="blue">laser vision</font> <font color="blue">correction</font> could lead  to product <font color="blue">liability</font>, malpractice or other claims <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>Also,  <font color="blue">complications</font> or side <font color="blue">effects could jeopardize</font> the <font color="blue">approval by</font> the US Food and  <font color="blue">Drug Administration </font>of the <font color="blue">excimer laser</font> for sale for <font color="blue">laser vision</font> <font color="blue">correction</font></td>
    </tr>
    <tr>
      <td>Although results of a <font color="blue">study showed</font> that the majority of patients experienced no  serious side effects seven years after <font color="blue">laser vision</font> <font color="blue">correction</font> using PRK,  <font color="blue">complications</font> may be identified in further long-term follow-up studies of PRK  There are no long-term studies on the side effects of LASIK, the procedure more  often performed in <font color="blue">recent years</font></td>
    </tr>
    <tr>
      <td>However, a study of patients five years after  LASIK reported the majority of patients had a <font color="blue">high overall satisfaction</font> of the  procedure</td>
    </tr>
    <tr>
      <td>There is <font color="blue">no independent industry source</font> for data on side effects or  <font color="blue">complications</font> from <font color="blue">laser vision</font> <font color="blue">correction</font></td>
    </tr>
    <tr>
      <td>Some of the possible side effects of <font color="blue">laser vision</font> <font color="blue">correction</font> are:         -    foreign body sensation,         -    pain or <font color="blue">discomfort</font>,         -    <font color="blue">sensitivity</font> to <font color="blue">bright lights</font>,         -    <font color="blue">blurred vision</font>,                                             20    <PAGE>         -    dryness or tearing,         -    <font color="blue">fluctuation</font> in vision,         -    night glare,         -    poor or <font color="blue">reduced visual quality</font>,         -    over<font color="blue">correction</font> or under<font color="blue">correction</font>,         -    <font color="blue">regression</font>, and         -    <font color="blue">corneal flap</font> or corneal healing <font color="blue">complications</font></td>
    </tr>
    <tr>
      <td>We believe that the percentage of patients who experience serious side  <font color="blue">effects as</font> a result of <font color="blue">laser vision</font> <font color="blue">correction</font> at our centers is <font color="blue">likely less</font>  than 1prca</td>
    </tr>
    <tr>
      <td>Laser vision <font color="blue">correction</font> may also involve the removal of  &amp;quote Bowmanapstas  membrane, &amp;quote  an <font color="blue">intermediate layer between</font> the <font color="blue">outer <font color="blue">corneal layer</font></font> and the middle  <font color="blue">corneal layer</font> of the eye</td>
    </tr>
    <tr>
      <td>Although <font color="blue">several studies</font> have <font color="blue"><font color="blue">demonstrate</font>d no</font>  <font color="blue"><font color="blue">significant</font> adverse reactions</font> to <font color="blue">excimer laser</font> removal of Bowmanapstas membrane, the  long-term effect of the removal of Bowmanapstas <font color="blue">membrane on patients</font> is unclear</td>
    </tr>
    <tr>
      <td>WE MAY BE UNABLE TO ENTER INTO OR MAINTAIN AGREEMENTS WITH DOCTORS OR OTHER       HEALTH CARE PROVIDERS ON SATISFACTORY TERMS         We will have <font color="blue">difficulty generating revenue</font> if we are unable to <font color="blue">enter into</font>  or maintain <font color="blue"><font color="blue">agreements</font> with doctors</font> or other <font color="blue"><font color="blue">health care</font> providers on</font>  satisfactory terms</td>
    </tr>
    <tr>
      <td>Most states prohibit us from practicing medicine, employing  doctors to <font color="blue">practice medicine on</font> our behalf or <font color="blue">employing <font color="blue">optometrists</font></font> to render  <font color="blue">optometric services on</font> our behalf</td>
    </tr>
    <tr>
      <td>In most states we may only own and manage  centers and <font color="blue">enter into</font> affiliations with doctors and other <font color="blue">health care</font>  providers</td>
    </tr>
    <tr>
      <td>Also, <font color="blue"><font color="blue">affiliated</font> doctors</font> have provided a <font color="blue"><font color="blue">significant</font> source</font> of  patients for our premium-priced centers and that is expected to continue</td>
    </tr>
    <tr>
      <td>Accordingly, the success of our business depends upon our ability to  <font color="blue">enter into</font> <font color="blue">agreements</font> on acceptable terms with a sufficient number of health  care providers, including <font color="blue">institutions</font> and eye care doctors to render or arrange  surgical and other <font color="blue">professional services at <font color="blue">facilities</font></font> we own or manage</td>
    </tr>
    <tr>
      <td>Our <font color="blue">expense levels will</font> be based, in part, on our <font color="blue"><font color="blue">expectations</font> as</font> to  <font color="blue">future revenues</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">actual revenue levels</font> were below <font color="blue">expectations</font>, our operating  results <font color="blue">would deteriorate</font></td>
    </tr>
    <tr>
      <td>Historically, our quarterly results of <font color="blue">operations</font>  have varied, and future results <font color="blue">may continue</font> to <font color="blue">fluctuate <font color="blue">significant</font>ly from</font>  quarter to quarter</td>
    </tr>
    <tr>
      <td>Accordingly, quarter-to-quarter comparisons of our operating  results may not be <font color="blue">meaningful</font> and should not be <font color="blue">relied upon as indications</font> of  our <font color="blue">future performance</font> or annual operating results</td>
    </tr>
    <tr>
      <td><font color="blue">Quarterly </font>results will  <font color="blue">depend on numerous factors</font>, including economic <font color="blue">conditions</font> in our geographic  markets, <font color="blue">market acceptance</font> of our services, seasonal factors and other factors  described in this Form 10-K         THE MARKET PRICE OF OUR COMMON SHARES MAY BE VOLATILE         Historically, the <font color="blue">market price</font> of our <font color="blue">common shares</font> has <font color="blue">been volatile</font></td>
    </tr>
    <tr>
      <td>For  example, the <font color="blue">market price</font> of our <font color="blue"><font color="blue">common shares</font> decreased from</font> a high of dlra53dtta50  to a low of dlra0dtta79 between July 1999 and March 2003, then increased to dlra13dtta13 by  April 2004</td>
    </tr>
    <tr>
      <td><font color="blue">As of March </font>10, 2006, the <font color="blue">last sale price</font> of our <font color="blue">common shares</font> was  dlra6dtta84</td>
    </tr>
    <tr>
      <td>Our <font color="blue">common shares</font> will likely be volatile in the future due to industry  <font color="blue">developments</font> and business-specific factors such as:         -    our ability to <font color="blue">effective</font>ly penetrate the <font color="blue">laser vision</font> <font color="blue">correction</font>            market;         -    the impact of OccuLogix on results of <font color="blue">operations</font>;         -    <font color="blue">perception</font> of the potential for <font color="blue">rheopheresis</font> for dry age-related            <font color="blue">macular degeneration</font>;         -    our ability to execute our business strategy;         -    new <font color="blue">technological innovation</font>s and products;         -    changes in <font color="blue"><font color="blue">government</font> <font color="blue">regulations</font></font>;         -    <font color="blue">adverse <font color="blue">regulatory</font> action</font>;         -    public <font color="blue">concerns about</font> the safety and <font color="blue"><font color="blue">effective</font>ness</font> of <font color="blue">laser vision</font>            <font color="blue">correction</font>;         -    loss of <font color="blue">key <font color="blue">management</font></font>;         -    <font color="blue"><font color="blue">announcement</font>s</font> of non-routine events such as <font color="blue">acquisitions</font> or            <font color="blue">litigation</font>;         -    <font color="blue">variations</font> in our financial results;         -    <font color="blue">fluctuation</font>s in <font color="blue">competitors</font> &amp;apos  stock prices;                                             21  <PAGE>         -    the issuance of new or changed stock market analyst reports and            <font color="blue">recommendations</font> <font color="blue">concerning</font> our <font color="blue">common shares</font> or <font color="blue">competitors</font> &amp;apos  stock;         -    changes in earnings estimates by securities analysts;         -    our ability to meet analysts &amp;apos  <font color="blue">projections</font>;         -    changes in the market for <font color="blue">medical services</font>; or         -    general economic, political and market <font color="blue">conditions</font></td>
    </tr>
    <tr>
      <td>In addition, in <font color="blue">recent years</font> the prices and <font color="blue">trading volumes</font> of publicly  traded shares, particularly those of companies in <font color="blue">health care</font> related markets,  have <font color="blue">been volatile</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">volatility</font> has <font color="blue">substantially</font> affected the <font color="blue">market price</font>s  of many companies &amp;apos  securities for <font color="blue">reasons frequently unrelated</font> or  <font color="blue">disproportionate</font> to their operating performance</td>
    </tr>
    <tr>
      <td><font color="blue">Following </font>the terrorist attacks  in the <font color="blue"><font color="blue">United States</font> </font>in September 2001, stock markets experienced <font color="blue">volatility</font> and  <font color="blue">stock prices declined</font>, in some cases <font color="blue">substantially</font></td>
    </tr>
    <tr>
      <td><font color="blue">Continued </font><font color="blue">volatility</font> may  reduce the <font color="blue">market price</font> of our <font color="blue">common shares</font></td>
    </tr>
    <tr>
      <td>WE MAY BE UNABLE TO EXECUTE OUR BUSINESS STRATEGY         Our business strategy is to be a <font color="blue">diversified <font color="blue">eye care services</font> company</font>,  leveraging our <font color="blue">relationships</font> with over 13cmam000 <font color="blue">ophthalmologists</font> and <font color="blue">optometrists</font>  <font color="blue">throughout</font> <font color="blue">North America </font>to 1) grow the core refractive business while 2)  continuing to expand the non-refractive business segment</td>
    </tr>
    <tr>
      <td>If we do not <font color="blue">successfully</font> execute this strategy or if the strategy is not  <font color="blue">effective</font>, we may be unable to maintain or grow our revenues and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>WE MAY MAKE INVESTMENTS THAT MAY NOT BE PROFITABLE         We make <font color="blue">investment</font>s that are intended to support our strategic business  purposes</td>
    </tr>
    <tr>
      <td>These <font color="blue">investment</font>s are <font color="blue">generally</font> made in companies in the <font color="blue">laser vision</font>  <font color="blue">correction</font> business or other <font color="blue">eye care services</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">successfully</font>  manage our current and future <font color="blue">investment</font>s, including ASC <font color="blue">investment</font>s, or if  these <font color="blue">investment</font>s are not profitable or do not generate the expected returns,  <font color="blue">then future</font> operating results may be <font color="blue"><font color="blue">adversely</font> impacted</font></td>
    </tr>
    <tr>
      <td>OUR GROWTH STRATEGY DEPENDS ON OUR ABILITY TO OPEN NEW CENTERS OR TO MAKE       ACQUISITIONS OR ENTER INTO AFFILIATION ARRANGEMENTS         The success of our <font color="blue">growth strategy will</font> be <font color="blue">dependent on increasing</font> the  number of <font color="blue">procedures at</font> our <font color="blue">eye care centers</font> and/or increasing the number of eye  <font color="blue">care centers through internal development</font> or <font color="blue">acquisitions</font> and <font color="blue">entering into</font>  affiliation <font color="blue">arrangements</font> with local eye care professionals in markets not large  enough to justify a <font color="blue">corporate center</font></td>
    </tr>
    <tr>
      <td>The addition of <font color="blue">new centers will present challenges</font> to us, including the  <font color="blue">integration</font> of new <font color="blue">operations</font>, <font color="blue">technologies</font> and personnel</td>
    </tr>
    <tr>
      <td>The addition of new  <font color="blue">centers also presents special risks</font>, including:         -    <font color="blue">unanticipated <font color="blue">liabilities</font></font> and <font color="blue">contingencies</font>;         -    diversion of <font color="blue"><font color="blue">management</font> attention</font>; and         -    <font color="blue">possible adverse effects on</font> operating results resulting from:              -    <font color="blue">possible future goodwill impairment</font>;              -    <font color="blue">increased interest costs</font>;              -    the issuance of <font color="blue">additional</font> securities; and              -    <font color="blue">increased costs</font> resulting <font color="blue">from difficulties</font> related to the                 <font color="blue">integration</font> of the acquired <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>Our ability to achieve growth through <font color="blue">acquisitions</font> will depend on a number  of factors, including:         -    the <font color="blue">availability</font> of <font color="blue">attractive acquisition opportunities</font>;         -    the <font color="blue">availability</font> of capital to complete <font color="blue">acquisitions</font>;         -    the <font color="blue">availability</font> of working capital to fund the <font color="blue">operations</font> of acquired            <font color="blue">businesses</font>; and         -    the effect of existing and emerging <font color="blue">competition</font> on <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">successfully</font> identify <font color="blue">suitable acquisition</font>  <font color="blue">candidates</font>, complete <font color="blue">acquisitions</font> on acceptable terms, if at all, or  <font color="blue">successfully</font> integrate acquired <font color="blue">businesses</font> into our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our past and  possible future <font color="blue">acquisitions</font> may not achieve <font color="blue">adequate levels</font> of revenue,  <font color="blue">profitability</font> or <font color="blue">productivity</font> or may not otherwise perform as expected</td>
    </tr>
    <tr>
      <td>22    <PAGE>         WE MAY BE UNABLE TO SUCCESSFULLY IMPLEMENT AND INTEGRATE NEW OPERATIONS AND       FACILITIES         Our <font color="blue">success depends on</font> our ability to manage our existing <font color="blue">operations</font> and  <font color="blue">facilities</font> and to expand our <font color="blue">businesses</font> consistent with our business strategy</td>
    </tr>
    <tr>
      <td>In the past, we have grown rapidly <font color="blue">in the <font color="blue">United States</font></font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future growth</font> and  <font color="blue">expansion will increase</font> our <font color="blue">management</font>apstas responsibilities and <font color="blue">demands on</font>  operating information <font color="blue">technologies</font> and <font color="blue">financial systems</font> and resources</td>
    </tr>
    <tr>
      <td>Our  business and financial results are <font color="blue">dependent upon</font> a number of factors, including  our ability to:         -    implement upgraded <font color="blue">operations</font>, information <font color="blue">technologies</font> and financial            systems, procedures and controls;         -    hire and <font color="blue">train new staff</font> and <font color="blue">managerial personnel</font>;         -    adapt or amend our business structure to <font color="blue">comply with</font> present or future            <font color="blue"><font color="blue">legal <font color="blue">requirements</font></font> affecting</font> our <font color="blue"><font color="blue">arrangements</font> with doctors</font>, including            state <font color="blue">prohibition</font>s on fee-splitting, corporate practice of optometry            and medicine and referrals to <font color="blue">facilities</font> in <font color="blue">which doctors</font> have a            <font color="blue">financial interest</font>;         -    obtain <font color="blue"><font color="blue">regulatory</font> approvals</font>, where <font color="blue">necessary</font>, and <font color="blue">comply with</font>            <font color="blue">licensing <font color="blue">requirements</font> applicable</font> to doctors and <font color="blue">facilities</font> operated,            and services offered, by doctors;         -    <font color="blue">successfully</font> integrate <font color="blue">acquisitions</font> into our existing business model;            and         -    <font color="blue">successfully</font> develop new <font color="blue">LASIK Select </font>centers and achieve growth and            <font color="blue">profitability</font> goals of those centers</td>
    </tr>
    <tr>
      <td>Our failure or <font color="blue">inability</font> to <font color="blue">successfully</font> implement these and other factors  <font color="blue">may <font color="blue">adversely</font> affect</font> the quality and <font color="blue">profitability</font> of our business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>WE DEPEND ON KEY PERSONNEL WHOSE LOSS COULD ADVERSELY AFFECT OUR BUSINESS         Our success and <font color="blue">growth depends</font> in part on the <font color="blue">active participation</font> of key  medical and <font color="blue"><font color="blue">management</font> personnel</font>, including Mr</td>
    </tr>
    <tr>
      <td>Elias Vamvakas, Chairman of the  <font color="blue">Board of Directors</font>, and Mr</td>
    </tr>
    <tr>
      <td>Wachtman and several key  <font color="blue">ophthalmologists</font></td>
    </tr>
    <tr>
      <td>Despite having this insurance in place, the loss of any one of  these <font color="blue">key <font color="blue">individuals</font> could <font color="blue">adversely</font> affect</font> the quality, <font color="blue">profitability</font> and  <font color="blue">growth prospects</font> of our business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">employment</font> or similar <font color="blue">agreements</font> with the above <font color="blue">individuals</font> and  other <font color="blue">key personnel</font></td>
    </tr>
    <tr>
      <td>The terms of these <font color="blue">agreements</font> include, in some cases,  <font color="blue">entitlements</font> to substantial <font color="blue">severance payments</font> in the event of <font color="blue">termination</font> of  <font color="blue">employment</font> by either us or the employee</td>
    </tr>
    <tr>
      <td>WE MAY BE SUBJECT TO MALPRACTICE AND OTHER SIMILAR CLAIMS AND MAY BE UNABLE       TO OBTAIN OR MAINTAIN ADEQUATE INSURANCE AGAINST THESE CLAIMS         The provision of <font color="blue">medical services</font> at our <font color="blue">centers entails</font> an <font color="blue">inherent risk</font>  of <font color="blue">potential malpractice</font> and other similar claims</td>
    </tr>
    <tr>
      <td><font color="blue">Beginning October </font>1, 2002,  all of our US <font color="blue">professional malpractice insurance</font> had a dlra250cmam000 deductible per  claim</td>
    </tr>
    <tr>
      <td>Patients at our centers execute <font color="blue">informed consent statements prior</font> to any  procedure performed <font color="blue">by doctors at</font> our centers, but these <font color="blue">consents may</font> not  provide adequate <font color="blue">liability</font> protection</td>
    </tr>
    <tr>
      <td>Although we do not engage in the practice  of medicine or have <font color="blue">responsibility</font> for <font color="blue"><font color="blue">compliance with</font> <font color="blue">regulatory</font></font> and other  <font color="blue"><font color="blue">requirements</font> directly applicable</font> to doctors and <font color="blue">doctor groups</font>, claims, suits or  <font color="blue">complaints</font> relating to <font color="blue">services provided at</font> our <font color="blue">centers may</font> be asserted against  us in the future, and the assertion or outcome of these claims could result in  <font color="blue">higher <font color="blue">administrative</font></font> and <font color="blue">legal expenses</font>, including <font color="blue">settlement costs</font> or  <font color="blue">litigation</font> damages</td>
    </tr>
    <tr>
      <td>We currently maintain <font color="blue">malpractice insurance coverage</font> and accruals that we  believe is <font color="blue">adequate both as</font> to risks and <font color="blue">amounts covered</font></td>
    </tr>
    <tr>
      <td>In addition, we  require the doctors who provide <font color="blue">medical services</font> at our centers to maintain  comprehensive professional <font color="blue">liability</font> insurance and most of these doctors have  agreed to <font color="blue">indemnify us against certain malpractice</font> and other claims</td>
    </tr>
    <tr>
      <td>Our  insurance coverage, however, may not be adequate to satisfy claims, insurance  maintained by the <font color="blue">doctors may</font> not <font color="blue">protect us</font> and <font color="blue">such indemnification may</font> not be  enforceable or, if enforced, may not be sufficient</td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to obtain  <font color="blue">adequate insurance</font> or an increase in the <font color="blue">future cost</font> of insurance to us and the  doctors who provide <font color="blue">medical services</font> at the <font color="blue">centers may</font> have a material adverse  effect on our business and financial results</td>
    </tr>
    <tr>
      <td>The <font color="blue">excimer laser</font> system uses <font color="blue">hazardous gases</font> which if not properly  <font color="blue">contained could</font> result in injury</td>
    </tr>
    <tr>
      <td>We may not have <font color="blue">adequate insurance</font> for any  <font color="blue">liabilities</font> arising <font color="blue">from injuries</font> caused by the <font color="blue">excimer laser</font> system or  <font color="blue">hazardous gases</font></td>
    </tr>
    <tr>
      <td>While we believe that any claims alleging defects in our  excimer <font color="blue">laser systems</font> would usually be <font color="blue">covered by</font> the <font color="blue">manufacturers</font> &amp;apos  product  <font color="blue">liability</font> insurance, the <font color="blue">manufacturers</font> of our excimer <font color="blue">laser systems</font> may not  continue to carry adequate product <font color="blue">liability</font> insurance</td>
    </tr>
    <tr>
      <td>23    <PAGE>         WE MAY FACE CLAIMS FOR FEDERAL, STATE AND LOCAL TAXES         We operate in 48 states and two <font color="blue">Canadian </font>provinces and are subject to  <font color="blue">various federal</font>, state and local income, payroll, un<font color="blue">employment</font>, property,  franchise, capital, sales and use tax on our <font color="blue">operations</font>, payroll, assets and  services</td>
    </tr>
    <tr>
      <td>We endeavor to <font color="blue">comply with</font> all <font color="blue">such applicable tax <font color="blue">regulations</font></font>, many  of which are subject to <font color="blue">different <font color="blue">interpretation</font>s</font>, and have <font color="blue">hired outside tax</font>  advisors who assist in the process</td>
    </tr>
    <tr>
      <td>Many states and other <font color="blue">taxing <font color="blue">authorities</font></font>  have <font color="blue">been interpreting laws</font> and <font color="blue">regulations</font> more <font color="blue">aggressively</font> to the detriment  of taxpayers</td>
    </tr>
    <tr>
      <td>We believe that we have <font color="blue">adequate provisions</font> and accruals in our  <font color="blue">financial statements</font> for tax <font color="blue">liabilities</font>, although we <font color="blue">cannot predict</font> the outcome  of <font color="blue">future tax <font color="blue">assessments</font></font></td>
    </tr>
    <tr>
      <td>Tax <font color="blue">authorities</font> in two states have <font color="blue">contacted us</font> and <font color="blue">issued proposed sales</font>  <font color="blue">tax <font color="blue">adjustments</font></font> in the <font color="blue">aggregate amount</font> of approximately dlra0dtta7 million for  various periods through 2005 on the basis that certain of our business  <font color="blue"><font color="blue">arrangements</font> constitute at least</font> a <font color="blue">partially taxable transaction rather than</font> an  <font color="blue">exempt service</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">discussions</font> with</font> these two state tax <font color="blue">authorities</font> are  ongoing</td>
    </tr>
    <tr>
      <td>If it is determined that any sales tax is owed, we believe that, under  <font color="blue">applicable laws</font> and our <font color="blue">contracts with</font> our customers, each customer is  <font color="blue">ultimately responsible</font> for the payment of any <font color="blue">applicable sales</font> and use taxes in  respect of our services</td>
    </tr>
    <tr>
      <td>However, we may be unable to collect any <font color="blue">such amounts</font>  from our customers, and in such event we <font color="blue">would remain responsible</font> for payment</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot yet predict</font> the outcome of these <font color="blue">outstanding <font color="blue">assessments</font></font> or any other  <font color="blue">assessments</font> or similar <font color="blue">actions which may</font> be <font color="blue">undertaken by</font> other state tax  <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>We have evaluated and implemented a <font color="blue">comprehensive sales tax</font>  reporting system</td>
    </tr>
    <tr>
      <td>We believe that we have <font color="blue">adequate provisions</font> in our financial  <font color="blue">statements with respect</font> to these matters</td>
    </tr>
    <tr>
      <td>COMPLIANCE WITH INDUSTRY REGULATIONS IS COSTLY AND BURDENSOME         Our <font color="blue">operations</font> are subject to extensive federal, state and <font color="blue">local laws</font>,  rules and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Our efforts to <font color="blue">comply with</font> these laws, rules and  <font color="blue">regulations</font> may impose <font color="blue">significant</font> costs, and failure to <font color="blue">comply with</font> these laws,  rules and <font color="blue">regulations</font> may result in fines or other charges being <font color="blue">imposed on us</font></td>
    </tr>
    <tr>
      <td>We have incurred <font color="blue">significant</font> costs, and expect to incur <font color="blue">additional</font> costs in  <font color="blue"><font color="blue"><font color="blue">connection</font> with</font> <font color="blue">compliance with</font></font> the provisions of the Sarbanes-Oxley Act of  2002</td>
    </tr>
    <tr>
      <td>Our failure to <font color="blue">comply with</font> the provisions of Sarbanes-Oxley, including  provision relating to internal financial controls, could have a material adverse  effect on us</td>
    </tr>
    <tr>
      <td>Many state laws limit or <font color="blue">prohibit <font color="blue">corporations</font> from practicing medicine</font> and  optometry, and many federal and state <font color="blue">laws extensively regulate</font> the <font color="blue">solicitation</font>  of <font color="blue">prospective patients</font>, the structure of our fees and our <font color="blue">contractual</font>  <font color="blue">arrangements</font> with hospitals, surgery centers, <font color="blue">ophthalmologists</font> and <font color="blue">optometrists</font>,  <font color="blue">among others</font></td>
    </tr>
    <tr>
      <td>Some states <font color="blue">also impose licensing <font color="blue">requirements</font></font></td>
    </tr>
    <tr>
      <td>Although we have  tried to structure our business and <font color="blue">contractual</font> <font color="blue">relationships</font> in <font color="blue">compliance with</font>  these laws in all material respects, if any aspect of our <font color="blue">operations</font> were found  to violate <font color="blue">applicable laws</font>, we could be subject to <font color="blue"><font color="blue">significant</font> fines</font> or other  penalties, required to cease <font color="blue">operations</font> in a particular <font color="blue">jurisdiction</font>, prevented  from commencing <font color="blue">operations</font> in a particular state or otherwise be required to  revise the structure of our business or <font color="blue">legal <font color="blue">arrangements</font></font></td>
    </tr>
    <tr>
      <td>Many of these laws  and <font color="blue">regulations</font> are <font color="blue">ambiguous</font>, have not been <font color="blue">definitively</font> interpreted by courts  or <font color="blue">regulatory</font> <font color="blue">authorities</font> and vary from <font color="blue">jurisdiction</font> to <font color="blue">jurisdiction</font></td>
    </tr>
    <tr>
      <td>Accordingly, we may not be able to <font color="blue">predict how</font> these laws and <font color="blue">regulations</font> will  be interpreted or <font color="blue">applied by courts</font> and <font color="blue">regulatory</font> <font color="blue">authorities</font>, and some of our  <font color="blue"><font color="blue">activities</font> could</font> be challenged</td>
    </tr>
    <tr>
      <td>Numerous <font color="blue"><font color="blue">legislative</font> proposals</font> to reform the US <font color="blue">health care</font> system have  <font color="blue">been introduced</font> in <font color="blue">Congress </font>and in various state <font color="blue">legislatures over</font> the past  <font color="blue">several years</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> whether any of these <font color="blue">proposals will</font> be adopted  and, if adopted, what impact this <font color="blue">legislation would</font> have on our business</td>
    </tr>
    <tr>
      <td>To  respond to any such changes, we could be required to revise the structure of our  <font color="blue">legal <font color="blue">arrangements</font></font> or the structure of our fees, incur substantial <font color="blue">legal fees</font>,  fines or other costs, or curtail some of our business <font color="blue">activities</font>, reducing the  <font color="blue">potential profit</font> of some of our <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>State <font color="blue">medical boards</font> and state boards of optometry <font color="blue">generally</font> set limits on  the <font color="blue">activities</font> of <font color="blue">ophthalmologists</font> and <font color="blue">optometrists</font></td>
    </tr>
    <tr>
      <td>In some instances, issues  have <font color="blue">been raised as</font> to <font color="blue">whether participation</font> in a co-<font color="blue">management</font> program violates  some of these limits</td>
    </tr>
    <tr>
      <td>If a state authority were to find that our co-<font color="blue">management</font>  program did not <font color="blue">comply with</font> state licensing laws, we would be required to revise  the structure of our <font color="blue">legal <font color="blue">arrangements</font></font> or curtail our <font color="blue">operations</font>, and  <font color="blue"><font color="blue">affiliated</font> doctors</font> might terminate their <font color="blue">relationships</font> with us</td>
    </tr>
    <tr>
      <td>Federal and state civil and criminal statutes impose penalties, including  substantial civil and criminal fines and <font color="blue">imprisonment</font>, on <font color="blue">health care</font> providers  and persons who provide services to <font color="blue">health care</font> providers, including <font color="blue">management</font>  <font color="blue">businesses</font> such as ours, for <font color="blue">fraudulently</font> or wrongfully billing <font color="blue">government</font> or  other insurers</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">federal law prohibiting false</font> Medicare/Medicaid  <font color="blue">billings allows</font> a private person to bring a <font color="blue">civil action</font> in the name of the US  <font color="blue">government</font> for violations of its provisions and obtain a portion of the damages  if the action is successful</td>
    </tr>
    <tr>
      <td>We believe that we are in material <font color="blue">compliance with</font>  these billing laws, but our business could be <font color="blue"><font color="blue">adversely</font> affected</font> if <font color="blue">government</font>al  <font color="blue">authorities</font> were to scrutinize or challenge our <font color="blue">activities</font> or <font color="blue">private parties</font>  were to assert a false claim or action <font color="blue">against us</font> in the name of the US  <font color="blue">government</font></td>
    </tr>
    <tr>
      <td>24    <PAGE>         Although we believe that we have obtained the <font color="blue">necessary</font> licenses or  <font color="blue"><font color="blue">certificate</font>s</font> of need in states where <font color="blue">such licenses</font> are required and that we are  not required to obtain any licenses in other states, some of the state  <font color="blue">regulations</font> governing the need for <font color="blue">such licenses</font> are unclear, and there is no  <font color="blue">applicable precedent</font> or <font color="blue">regulatory</font> guidance to <font color="blue">help resolve</font> these issues</td>
    </tr>
    <tr>
      <td>A  state <font color="blue">regulatory</font> authority could determine that we are operating a center  <font color="blue">inappropriately without</font> a required license or <font color="blue">certificate</font> of need, <font color="blue">which could</font>  subject us to <font color="blue"><font color="blue">significant</font> fines</font> or other penalties, result in us being required  to cease <font color="blue">operations</font> in a state or <font color="blue">otherwise jeopardize</font> our business and  financial results</td>
    </tr>
    <tr>
      <td>If we expand to a <font color="blue">new geographic market</font>, we may be unable to  obtain any new license required in that <font color="blue">jurisdiction</font></td>
    </tr>
    <tr>
      <td>COMPLIANCE WITH ADDITIONAL HEALTH CARE REGULATIONS IN CANADA IS COSTLY AND       BURDENSOME         Some <font color="blue">Canadian </font>provinces have <font color="blue">adopted conflict</font> of interest <font color="blue">regulations</font> that  prohibit <font color="blue">optometrists</font>, <font color="blue">ophthalmologists</font> or <font color="blue">corporations</font> they own or <font color="blue">control from</font>  receiving <font color="blue">benefits from suppliers</font> of medical goods or services to whom they  <font color="blue">refer patients</font></td>
    </tr>
    <tr>
      <td>The laws of some <font color="blue">Canadian </font>provinces also prohibit <font color="blue">health care</font>  professionals from splitting fees with non-<font color="blue">health care</font> professionals and  prohibit non-licensed entities such as us from practicing medicine or optometry  and <font color="blue">from directly employing physicians</font> or <font color="blue">optometrists</font></td>
    </tr>
    <tr>
      <td>We believe that we are  in material <font color="blue">compliance with</font> these <font color="blue">requirements</font>, but a review of our <font color="blue">operations</font>  by <font color="blue">Canadian </font><font color="blue">regulators</font> or changes in the <font color="blue">interpretation</font> or <font color="blue">enforcement</font> of  existing <font color="blue">Canadian </font><font color="blue">legal <font color="blue">requirements</font></font> or the adoption of <font color="blue">new <font color="blue">requirements</font> could</font>  require us to <font color="blue">incur <font color="blue">significant</font> costs</font> to <font color="blue">comply with</font> laws and <font color="blue">regulations</font> in the  future or require us to change the structure of our <font color="blue"><font color="blue">arrangements</font> with doctors</font></td>
    </tr>
    <tr>
      <td>COMPLIANCE WITH US FOOD AND DRUG ADMINISTRATION REGULATIONS REGARDING THE       USE OF EXCIMER LASER SYSTEMS FOR LASER VISION CORRECTION IS COSTLY AND       BURDENSOME         To date, the FDA has approved excimer <font color="blue">laser systems</font> manufactured by some  <font color="blue">manufacturers</font> for sale for the treatment of nearsightedness, farsightedness and  <font color="blue">astigmatism up</font> to stated levels of <font color="blue">correction</font></td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> applicable  FDA <font color="blue"><font color="blue">requirements</font> with respect</font> to the use of the <font color="blue">excimer laser</font> could subject us,  our <font color="blue"><font color="blue">affiliated</font> doctors</font> or laser <font color="blue">manufacturers</font> to <font color="blue">enforcement</font> action, including  product seizure, recalls, withdrawal of approvals and civil and criminal  penalties</td>
    </tr>
    <tr>
      <td>The FDA has <font color="blue">adopted <font color="blue">guidelines</font></font> in <font color="blue"><font color="blue">connection</font> with</font> the approval of excimer  <font color="blue">laser systems</font> for <font color="blue">laser vision</font> <font color="blue">correction</font></td>
    </tr>
    <tr>
      <td>The FDA, however, has also stated  that <font color="blue">decisions by doctors</font> and patients to <font color="blue">proceed outside</font> the FDA-approved  <font color="blue">guidelines</font> are a practice of medicine decision, which the FDA is not authorized  to regulate</td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> FDA <font color="blue">requirements</font> or any adverse FDA action,  including a reversal of its <font color="blue">interpretation</font> with respect to the practice of  medicine, could result in a <font color="blue">limitation on</font> or <font color="blue">prohibition</font> of our use of excimer  lasers</td>
    </tr>
    <tr>
      <td><font color="blue">Discovery </font>of problems, violations of current laws or future <font color="blue">legislative</font> or  <font color="blue">administrative</font> action in the <font color="blue"><font color="blue">United States</font> </font>or elsewhere <font color="blue">may <font color="blue">adversely</font> affect</font> the  laser <font color="blue">manufacturers</font> &amp;apos  ability to obtain <font color="blue">regulatory</font> approval of laser equipment</td>
    </tr>
    <tr>
      <td>Furthermore, the failure of other <font color="blue">excimer laser</font> <font color="blue">manufacturers</font> to <font color="blue">comply with</font>  <font color="blue">applicable federal</font>, state or foreign <font color="blue">regulatory</font> <font color="blue">requirements</font>, or any adverse  <font color="blue">action against</font> or involving such <font color="blue">manufacturers</font>, could limit the supply of  <font color="blue"><font color="blue">excimer laser</font>s</font>, <font color="blue">substantially</font> increase the cost of <font color="blue"><font color="blue">excimer laser</font>s</font>, limit the  number of patients that can be <font color="blue">treated at</font> our centers and limit our ability to  use <font color="blue"><font color="blue">excimer laser</font>s</font></td>
    </tr>
    <tr>
      <td>Most of our <font color="blue">eye care centers</font> and access sites in the <font color="blue"><font color="blue">United States</font> </font>use VISX  and/or <font color="blue">Alcon Laboratories Inc</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">excimer laser</font>s</font></td>
    </tr>
    <tr>
      <td>If VISX, Alcon or other excimer  laser <font color="blue">manufacturers</font> fail to <font color="blue">comply with</font> <font color="blue">applicable federal</font>, state or foreign  <font color="blue">regulatory</font> <font color="blue">requirements</font>, or if any <font color="blue">adverse <font color="blue">regulatory</font> action</font> is <font color="blue">taken against</font> or  involves such <font color="blue">manufacturers</font>, the supply of <font color="blue">lasers could</font> be limited and the cost  of <font color="blue"><font color="blue">excimer laser</font>s</font> could increase</td>
    </tr>
    <tr>
      <td>The Roll-On/Roll-Off <font color="blue">laser system consists</font> of an <font color="blue">excimer laser</font> mounted on a  motorized, air suspension platform and transported in a <font color="blue">specially modified</font>  truck</td>
    </tr>
    <tr>
      <td>We believe that use of this <font color="blue">transport system</font> does not require FDA  approval; the FDA has <font color="blue">taken no position</font> in regard to <font color="blue">such approval</font></td>
    </tr>
    <tr>
      <td><font color="blue">The FDA  </font>could, however, take the position that <font color="blue"><font color="blue">excimer laser</font>s</font> are not approved for use  in this <font color="blue">transport system</font></td>
    </tr>
    <tr>
      <td>Such a view by the FDA could lead to an <font color="blue">enforcement</font>  action <font color="blue">against us</font>, <font color="blue">which could</font> impede our ability to maintain or increase our  volume of <font color="blue">excimer laser</font> surgeries</td>
    </tr>
    <tr>
      <td>Similarly, we believe that FDA approval is  not required for our <font color="blue">mobile use</font> of <font color="blue">microkeratomes</font> or the <font color="blue">cataract equipment</font>  <font color="blue">transported by</font> our mobile cataract <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The FDA, however, could take a  <font color="blue">contrary position</font> that could result in an <font color="blue">enforcement</font> action</td>
    </tr>
    <tr>
      <td>DISPUTES WITH RESPECT TO INTELLECTUAL PROPERTY COULD ADVERSELY AFFECT OUR       BUSINESS         There has been substantial <font color="blue">litigation</font> in the <font color="blue"><font color="blue">United States</font> </font>and Canada  regarding the <font color="blue">patents on ophthalmic lasers</font></td>
    </tr>
    <tr>
      <td>Although we <font color="blue">currently lease</font> or  purchase <font color="blue"><font color="blue">excimer laser</font>s</font> and other <font color="blue">technology from</font> the <font color="blue">manufacturers</font>, if the use  of an <font color="blue">excimer laser</font> or other procedure performed at any of our centers is deemed  to infringe a patent or other <font color="blue">proprietary</font> right, we may be <font color="blue">prohibited from using</font>  the equipment or performing the procedure that is the subject of the patent  dispute or may be required to obtain a royalty-bearing                                             25    <PAGE>    license, which may involve substantial costs, including <font color="blue">ongoing royalty</font>  payments</td>
    </tr>
    <tr>
      <td>We have <font color="blue">also secured patents</font> for portions of the equipment we use to  transport our <font color="blue">mobile lasers</font></td>
    </tr>
    <tr>
      <td>Our patents and other <font color="blue">proprietary</font> technology are  important to our success</td>
    </tr>
    <tr>
      <td>These <font color="blue">patents could</font> be challenged, invalidated or  <font color="blue">circumvented</font> in the future</td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>regarding <font color="blue"><font color="blue">intellectual</font> property</font> is common  and our <font color="blue">patents may</font> not <font color="blue">adequately protect</font> our <font color="blue"><font color="blue">intellectual</font> property</font></td>
    </tr>
    <tr>
      <td><font color="blue">Defending  </font>and prosecuting <font color="blue"><font color="blue">intellectual</font> property</font> <font color="blue">proceedings</font> is costly and involves  substantial <font color="blue">commitments</font> of <font color="blue">management</font> time</td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">successfully</font> defend  our <font color="blue">rights with respect</font> to our <font color="blue"><font color="blue">intellectual</font> property</font>, we may be required to pay  damages and <font color="blue">cease using</font> our equipment to transport <font color="blue">mobile lasers</font>, which may have  a material adverse effect on our business</td>
    </tr>
    <tr>
      <td>WE MAY NOT HAVE THE CAPITAL RESOURCES NECESSARY IN ORDER TO KEEP UP WITH       RAPID TECHNOLOGICAL CHANGES         Modern <font color="blue">medical technology</font> changes rapidly</td>
    </tr>
    <tr>
      <td>New or enhanced <font color="blue">technologies</font> and  therapies may be developed with better performance or lower costs than the laser  vision <font color="blue">correction</font> currently provided at our centers</td>
    </tr>
    <tr>
      <td>We may not have the capital  resources to upgrade our <font color="blue"><font color="blue">excimer laser</font> equipment</font>, acquire new or enhanced  <font color="blue">medical devices</font> or <font color="blue">adopt new</font> or enhanced <font color="blue">procedures at</font> the time that any  <font color="blue">advanced technology</font> or therapy is introduced</td>
    </tr>
    <tr>
      <td>THE ABILITY OF OUR SHAREHOLDERS TO EFFECT CHANGES IN CONTROL OF OUR COMPANY       IS LIMITED         We have a <font color="blue"><font color="blue">shareholder</font> rights</font> plan <font color="blue">which enables</font> the <font color="blue"><font color="blue">Board of Directors</font> </font>to  delay a change in control of our company</td>
    </tr>
    <tr>
      <td>This <font color="blue">could discourage</font> a <font color="blue">third party</font>  <font color="blue">from attempting</font> to acquire control of our company, even if an <font color="blue">attempt would</font> be  <font color="blue">beneficial</font> to the interests of the <font color="blue"><font color="blue">shareholder</font>s</font></td>
    </tr>
    <tr>
      <td>In addition, since we are a  <font color="blue">Canadian </font>corporation, <font color="blue">investment</font>s in our <font color="blue">company may</font> be subject to the  provisions of the <font color="blue"><font color="blue">Investment Canada </font>Act</font></td>
    </tr>
    <tr>
      <td>In general, this act provides a system  for the <font color="blue">notification</font> to the <font color="blue">Investment Canada </font>agency of <font color="blue">acquisitions</font> of <font color="blue">Canadian </font> <font color="blue">businesses</font> by non-<font color="blue">Canadian </font>investors and for the review by the <font color="blue">Investment Canada </font> agency of <font color="blue">acquisitions</font> that <font color="blue">meet thresholds specified</font> in the act</td>
    </tr>
    <tr>
      <td>To the extent  that a non-<font color="blue">Canadian </font>person or company attempted to acquire 33prca or more of our  outstanding <font color="blue">common stock</font>, the threshold for a <font color="blue">presumption</font> of control, the  <font color="blue">transaction could</font> be <font color="blue">reviewable by</font> the <font color="blue">Investment Canada </font>agency</td>
    </tr>
    <tr>
      <td>The Investment  Canada Act <font color="blue">also applies</font> to a change of <font color="blue">control effected by</font> a sale of all or  <font color="blue">substantially</font> all of the assets of our company</td>
    </tr>
    <tr>
      <td>These factors and <font color="blue">others could</font>  have the effect of delaying, deferring or preventing a change of control of our  company supported by <font color="blue"><font color="blue">shareholder</font>s</font> but opposed by our <font color="blue">Board of Directors</font></td>
    </tr>
    <tr>
      <td>AS THE MAJORITY OWNER OF OCCULOGIX, IT MAY BE NECESSARY FOR US TO FUND       ADDITIONAL CAPITAL REQUIREMENTS         OccuLogix reported approximately dlra41dtta3 million of cash and short-term  <font color="blue">investment</font>s as of <font color="blue">December </font>31, 2005, largely as a result of its <font color="blue">initial public</font>  offering in <font color="blue">December </font>2004</td>
    </tr>
    <tr>
      <td>Although it expects the <font color="blue">current cash</font> and short-term  <font color="blue">investment</font>s to be adequate to support its <font color="blue">operations</font> for at least the next 12  months, OccuLogix anticipates that the funding <font color="blue">requirements</font> for its <font color="blue">activities</font>  <font color="blue">will continue</font> to increase <font color="blue">substantially</font>, primarily due to its efforts to achieve  FDA approval for and to <font color="blue">commercialize</font> the RHEO(TM) System</td>
    </tr>
    <tr>
      <td>OccuLogix may need to  seek <font color="blue">additional</font> funds in the future, and it may be <font color="blue">necessary</font> for us to fund  OccuLogixapstas <font color="blue">additional</font> capital <font color="blue">requirements</font> as the <font color="blue">majority <font color="blue">shareholder</font></font> in order  to <font color="blue">avoid dilution</font> of the value of our ownership</td>
    </tr>
    <tr>
      <td>THERE IS NO GUARANTEE THAT OCCULOGIX WILL BE SUCCESSFUL IN OBTAINING FDA       APPROVAL OR COMMERCIALIZING THE RHEO(TM) SYSTEM         On <font color="blue">February </font>3, 2006, OccuLogix announced that, <font color="blue">based on</font> a <font color="blue">preliminary</font>  analysis of the data from MIRA-1 (a pivotal clinical trial), MIRA-1 did not meet  its <font color="blue"><font color="blue">primary efficacy</font> endpoint as</font> it did not <font color="blue">demonstrate</font> a <font color="blue">statistically</font>  <font color="blue"><font color="blue">significant</font> difference</font> in the mean change of Best Spectacle-Corrected Visual  Acuity applying the Early Treatment Diabetic Retinopathy Scale, or ETDRS BCVA,  between the treated and <font color="blue">placebo groups</font> in MIRA-1 at 12 months post-baseline</td>
    </tr>
    <tr>
      <td>As  expected, the treated group <font color="blue">demonstrate</font>d a positive result</td>
    </tr>
    <tr>
      <td>An <font color="blue">anomalous</font>  response of the control group is the <font color="blue">principal reason</font> why the <font color="blue">primary efficacy</font>  endpoint was not met</td>
    </tr>
    <tr>
      <td>There were subgroups that did <font color="blue">demonstrate</font> statistical  significance in their mean change of ETDRS BCVA <font color="blue">versus control</font></td>
    </tr>
    <tr>
      <td>OccuLogix is in  the process of <font color="blue">analyzing further</font> the study data</td>
    </tr>
    <tr>
      <td>To that end, OccuLogix had enrolled a total of 185 patients  in MIRA-1 as of <font color="blue">December </font>31, 2004</td>
    </tr>
    <tr>
      <td><font color="blue">On November </font>17, 2005, OccuLogix announced  that it had collected complete 12-month post-treatment <font color="blue">data sets</font> for 169 of  these patients</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2004, OccuLogix had <font color="blue">also submitted</font> to the FDA  the first three of four modules of the Pre-market Approval Application, or PMA,  filing, the non-clinical portion</td>
    </tr>
    <tr>
      <td>The non-clinical portion of the PMA consisted  of <font color="blue">technical data</font> relating to <font color="blue">components</font> of the RHEO(TM) System</td>
    </tr>
    <tr>
      <td>Although  OccuLogix had intended to submit the fourth module, <font color="blue">which consists</font> of the  follow-up clinical data, in two <font color="blue">components</font>, following <font color="blue">discussions</font>                                             26    <PAGE>    with the FDA, it <font color="blue">subsequently elected</font> to <font color="blue">file only one</font> PMA clinical module  <font color="blue">following completion</font> of the 12-month data on at least 150 <font color="blue">data sets</font></td>
    </tr>
    <tr>
      <td><font color="blue">Subsequent to the <font color="blue">February </font></font>3, 2006 <font color="blue">announcement</font>, OccuLogix completed an  in-depth analysis of the MIRA-1 study data identifying subjects that were  included in the intent-to-treat, or ITT, <font color="blue">population but</font> who <font color="blue">deviated from</font> the  MIRA-1 <font color="blue">protocol as well as</font> those patients who had <font color="blue">documented losses</font> or gains in  vision for reasons not related to <font color="blue">retinal disease such as cataracts</font></td>
    </tr>
    <tr>
      <td>Those  subjects in the ITT population who met the protocol <font color="blue">requirements</font>, and who did  not <font color="blue">exhibit ophthalmic</font> changes unrelated to retinal disease, comprised the  modified per-protocol population</td>
    </tr>
    <tr>
      <td>In the modified per-protocol analysis, eyes treated with RHEO(TM) Therapy  <font color="blue">demonstrate</font>d a <font color="blue">mean vision gain</font> of 0dtta8 lines of ETDRS BCVA at 12 months  post-baseline, compared to a <font color="blue">mean vision loss</font> of 0dtta1 lines of ETDRS BCVA in the  eyes of the placebo group</td>
    </tr>
    <tr>
      <td>The result was <font color="blue">statistically</font> <font color="blue">significant</font> (repeated  measure p value = 0dtta0147)</td>
    </tr>
    <tr>
      <td>The <font color="blue">following table presents</font> a summary of the ETDRS  BCVA changes observed 12 months post-baseline in the modified per-protocol  analysis of MIRA-1:    <TABLE>  <CAPTION>                                            Treatment Group   Placebo Group                                                 (n=69)           (n=46)                                            ---------------   -------------  <S>                                       <C>               <C>  Vision <font color="blue">improvement greater</font> or equal to:  1 line                                         46dtta4prca            19dtta6prca  2 lines                                        27dtta5prca             8dtta7prca  3 lines                                         8dtta7prca             2dtta2prca  Vision <font color="blue">loss greater</font> or equal to:  1 line                                         11dtta6prca            23dtta9prca  2 lines                                         5dtta8prca             6dtta5prca  3 lines                                         2dtta9prca             2dtta2prca  </TABLE>         Within the modified per-protocol population with pre-treatment vision worse  than 20/40, 50dtta0prca of RHEO(TM) Therapy-treated <font color="blue">eyes improved</font>, after treatment, to  20/40 or better and would be able to qualify for a driverapstas license 12 months  post-baseline, compared to 20dtta0prca of <font color="blue">placebo eyes</font></td>
    </tr>
    <tr>
      <td>OccuLogix will be re-evaluating its PMA <font color="blue">submission strategy</font></td>
    </tr>
    <tr>
      <td>The  per-protocol population analysis comprises 115 complete <font color="blue">data sets</font>, while  OccuLogix had been required to obtain a minimum of 150 complete <font color="blue">data sets</font></td>
    </tr>
    <tr>
      <td>OccuLogix is planning to <font color="blue">meet with representatives</font> of the FDA in the second  quarter of 2006 in order to discuss the <font color="blue">impact on</font> the PMA <font color="blue">submission strategy</font> of  the MIRA-1 study results and the fact of the per-protocol population being fewer  than 150</td>
    </tr>
    <tr>
      <td>It is more <font color="blue">likely than</font> not that OccuLogix will be required to conduct  a follow-up clinical trial of the RHEO(TM) System</td>
    </tr>
    <tr>
      <td>However, until OccuLogix has  <font color="blue"><font color="blue">discussions</font> with</font> the FDA, it will not know if a follow-up clinical trial will be  <font color="blue">necessary</font> and, if one is <font color="blue">necessary</font>, what its nature, size, scope or duration  will be</td>
    </tr>
    <tr>
      <td>OccuLogix <font color="blue">cannot begin <font color="blue">commercialization</font></font> in the <font color="blue"><font color="blue">United States</font> </font>until it  receives FDA approval</td>
    </tr>
    <tr>
      <td>Until OccuLogix has <font color="blue"><font color="blue">discussions</font> with</font> the FDA, it will not  be able to anticipate when, if ever, it will receive FDA approval</td>
    </tr>
    <tr>
      <td>Accordingly,  at this time, OccuLogix does not know when it can expect to begin to generate  revenues <font color="blue">in the <font color="blue">United States</font></font></td>
    </tr>
    <tr>
      <td>Prior to the <font color="blue"><font color="blue">announcement</font> on</font> <font color="blue">February </font>3, 2006 of the <font color="blue">preliminary</font> analysis  of the data from MIRA-1, in <font color="blue">anticipation</font> of <font color="blue">commercialization</font> in the United  States, OccuLogix was <font color="blue">establishing</font> a plan to <font color="blue">educate members</font> of the eye care  <font color="blue">community about</font> RHEO(TM) Therapy</td>
    </tr>
    <tr>
      <td>It was in the process of identifying  multi-facility <font color="blue">health care</font> service providers, including hospitals, dialysis  clinics and ambulatory surgery centers, as well as private practices, which it  believes may be interested in providing RHEO(TM) Therapy in their <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>One of these potential providers may be TLCVision due to our <font color="blue">relationships</font> with  a large number of <font color="blue">optometrists</font> and <font color="blue">ophthalmologists</font> <font color="blue">in the <font color="blue">United States</font></font></td>
    </tr>
    <tr>
      <td>Pending the outcome of its <font color="blue"><font color="blue">discussions</font> with</font> the FDA and the de<font color="blue">termination</font> of the  <font color="blue">parameters</font> of any follow-up clinical trial of the RHEO(TM) System, OccuLogix has  suspended, for the time being, all of its <font color="blue">activities</font> that were being conducted  in <font color="blue">anticipation</font> of <font color="blue">commercialization</font> <font color="blue">in the <font color="blue">United States</font></font></td>
    </tr>
    <tr>
      <td>In 2003, OccuLogix received <font color="blue">Health Canada </font>approval for the <font color="blue">components</font> of  the RHEO(TM) System</td>
    </tr>
    <tr>
      <td>The <font color="blue">approval allows</font> OccuLogix to market the RHEO(TM) System  in Canada for use in the treatment of <font color="blue">patients suffering from dysproteinemia</font>  due, for example, to abnormal plasma viscosity and/or macular disease</td>
    </tr>
    <tr>
      <td>Upon  receiving the approval, OccuLogix began limited <font color="blue">commercialization</font> of the  RHEO(TM) System <font color="blue">through sales</font> of OctoNova pumps and <font color="blue">disposable <font color="blue">treatment sets</font></font> to  <font color="blue">three clinics</font> in Canada</td>
    </tr>
    <tr>
      <td><font color="blue">In September </font>2004, OccuLogix signed an <font color="blue">agreement with</font> a  private <font color="blue">Canadian </font><font color="blue">company called</font> Rheo Therapeutics Inc</td>
    </tr>
    <tr>
      <td>) ( &amp;quote Veris &amp;quote ), a provider of RHEO(TM) Therapy, <font color="blue">which agreed</font> to  purchase approximately 8cmam000 <font color="blue">treatment sets</font> and 20 OctoNova pumps by the end of  2005, with an option to <font color="blue">purchase up</font> to an <font color="blue">additional</font> 2cmam000 <font color="blue">treatment sets</font>,  subject to <font color="blue">availability</font></td>
    </tr>
    <tr>
      <td>However, due to delays in its plans to open a number of  <font color="blue">commercial treatment centers</font> in various <font color="blue">Canadian </font>cities where RHEO(TM)                                             27    <PAGE>    Therapy would be performed, Veris no longer required the contracted-for number  of <font color="blue">treatment sets</font> for such period</td>
    </tr>
    <tr>
      <td>OccuLogix agreed to keep the <font color="blue">original pricing</font>  for a reduced number of <font color="blue">treatment sets</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">December </font>2005, by letter agreement,  OccuLogix agreed to the volume and other terms for the purchase and sale of  <font color="blue">treatment sets</font> and pumps for the period ending <font color="blue">February </font>28, 2006</td>
    </tr>
    <tr>
      <td>OccuLogix  intends to <font color="blue">negotiate with</font> Veris <font color="blue">purchase orders</font> for the future</td>
    </tr>
    <tr>
      <td>Jeffery  Machat, who is an investor in and one of the <font color="blue">directors</font> of Veris, was a  co-founder and <font color="blue">former director</font> of our Company</td>
    </tr>
    <tr>
      <td>In summary, OccuLogixapstas primary <font color="blue">activities</font> to date have included  <font color="blue">commercialization</font> of the RHEO(TM) System in Canada, working to obtain FDA  <font color="blue">regulatory</font> approval for the RHEO(TM) System and building an operating  <font color="blue">infrastructure</font> to support potential US sales following <font color="blue">approval by</font> the FDA  Pending the outcome of OccuLogixapstas <font color="blue"><font color="blue">discussions</font> with</font> the FDA regarding the full  analysis of the MIRA-1 study data, it is <font color="blue"><font color="blue">reasonably</font> likely</font> that the focus of its  primary <font color="blue">activities</font> will shift</td>
    </tr>
    <tr>
      <td>OUR STOCK PRICE AND REPORTED RESULTS MAY BE IMPACTED BY THE OPERATING       RESULTS OF OCCULOGIX         As a <font color="blue">significant</font> <font color="blue">shareholder</font> of OccuLogix, our <font color="blue">stock price may</font> be affected  by changes in the price of OccuLogixapstas <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We are unable to predict  how <font color="blue">fluctuation</font>s in OccuLogixapstas stock price will affect our own stock price</td>
    </tr>
    <tr>
      <td>Because we have a <font color="blue">controlling</font> <font color="blue">financial interest</font> in OccuLogix, the results of  <font color="blue">operations</font> of this entity are <font color="blue">consolidated</font> into the operating results of our  other <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>OccuLogix expects to continue to report <font color="blue">significant</font> operating  losses for the <font color="blue">next <font color="blue">several years</font></font></td>
    </tr>
    <tr>
      <td>Because of the <font color="blue">numerous risks</font> and  <font color="blue">uncertainties associated with</font> developing and <font color="blue">commercializing new medical</font>  therapies, including obtaining FDA approval, OccuLogix is unable to predict the  extent of any <font color="blue">future losses</font> or when it <font color="blue">will become profitable</font>, if ever</td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>we are a <font color="blue">significant</font> <font color="blue">shareholder</font> of OccuLogix, our operating results and stock  price may be <font color="blue">negatively impact</font>ed by the operating results of OccuLogix</td>
    </tr>
    <tr>
      <td>In the  event that we were to reduce our ownership interest to the level where  <font color="blue">consolidation</font> was not required, our operating results <font color="blue">would still</font> be <font color="blue">impacted by</font>  OccuLogix to the extent of our ownership, via earnings from equity <font color="blue">investment</font>s</td>
    </tr>
    <tr>
      <td>As noted previously, on <font color="blue">February </font>3, 2006, OccuLogix announced that the  <font color="blue">preliminary</font> analysis of the data from MIRA-1 indicated that MIRA-1 did not  <font color="blue">demonstrate</font> a <font color="blue">statistically</font> <font color="blue">significant</font> mean change of BCVA As a result, the  share price of OccuLogixapstas <font color="blue">stock as traded on</font> the <font color="blue">NASDAQ National Market System  </font>decreased from dlra12dtta75 on <font color="blue">February </font>2, 2006 to close at dlra4dtta10 on <font color="blue">February </font>3, 2006</td>
    </tr>
    <tr>
      <td>The 10-day average price of the <font color="blue">stock immediately following</font> the <font color="blue">announcement</font> was  dlra3dtta65 and reflected a decrease in the <font color="blue">market capitalization</font> of OccuLogix from  dlra536dtta6 million on <font color="blue">February </font>2, 2006 to dlra153dtta6 million <font color="blue">based on</font> the 10-day average  share price after the <font color="blue">announcement</font></td>
    </tr>
    <tr>
      <td>The resulting decrease in the share price  was identified as an indicator of <font color="blue">impairment leading</font> to an analysis of  OccuLogixapstas <font color="blue">intangible assets</font> and goodwill and resulting in OccuLogix reporting  an <font color="blue">impairment charge</font> to goodwill of dlra147dtta5 million</td>
    </tr>
    <tr>
      <td>Because we accounted for the  OccuLogix <font color="blue">reorganization at historical cost</font>, we eliminate OccuLogixapstas goodwill  balance in <font color="blue">consolidation</font> (see Note 1)</td>
    </tr>
    <tr>
      <td>OccuLogix believes that the <font color="blue">announcement</font> made it unlikely that it would be  able to <font color="blue">collect on amounts outstanding from</font> its <font color="blue">sole customer</font>, Veris, resulting  in a provision for bad debts of dlra0dtta5 million related to revenue reported prior  to <font color="blue">December </font>2005</td>
    </tr>
    <tr>
      <td>OccuLogix did not recognize dlra0dtta5 million of revenue related to  goods shipped in <font color="blue">December </font>2005, <font color="blue">based on</font> collectibility not being <font color="blue">reasonably</font>  assured</td>
    </tr>
    <tr>
      <td>OccuLogix <font color="blue">also fully expensed</font> the dlra0dtta2 million advance that it had paid  to Veris in <font color="blue"><font color="blue">connection</font> with</font> clinical trial services to be provided by Veris for  one of OccuLogixapstas <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>OccuLogix <font color="blue">also evaluated</font> its ending  <font color="blue">inventory balance as</font> of <font color="blue">December </font>31, 2005 on the basis that Veris may not be  able to increase its commercial <font color="blue">activities</font> in Canada in line with initial  <font color="blue">expectations</font></td>
    </tr>
    <tr>
      <td>Accordingly, OccuLogix set up a provision for obsolescence of dlra2dtta0  million for <font color="blue">filter sets</font> that are unlikely to be <font color="blue">utilized prior</font> to their  <font color="blue">expiration dates</font></td>
    </tr>
    <tr>
      <td>As a result of the above entries, our reported pre-tax  earnings for the quarter and year ended <font color="blue">December </font>31, 2005 were reduced by dlra1dtta6  million</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font><font color="blue">adjustments</font> to asset values may be required as OccuLogix  continues its <font color="blue">evaluation</font> and <font color="blue">operations</font>, and those <font color="blue">adjustments</font> may be material</td>
    </tr>
    <tr>
      <td>Those <font color="blue">adjustments</font> could impact our <font color="blue">stock price as well as</font> our results to the  extent of our <font color="blue">ownership percentage</font> in OccuLogix</td>
    </tr>
  </tbody>
</table>